WVP
KPTI icon

Worth Venture Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Worth Venture Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,732
Closed -$598K – 152
2023
Q3 		$598K Hold
29,732
– – 0.35% 73
2023
Q2 		$798K Buy
+29,732
New +$1.28M 0.43% 57

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Worth Venture Partners's KPTI Position: Q4 2023 in Review

Worth Venture Partners sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 29,732 shares — an estimated $598K sold.

Worth Venture Partners first reported a position in KPTI in Q2 2023 and held it in 2 quarters. The position peaked at $798K in Q2 2023. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

  • Worth Venture Partners reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Worth Venture Partners sold 29,732 Karyopharm Therapeutics shares in Q4 2023, an estimated $598K.
  • Worth Venture Partners first reported a position in Karyopharm Therapeutics in Q2 2023 and held it in 2 quarters.
  • Worth Venture Partners's Karyopharm Therapeutics position peaked at $798K in Q2 2023.
  • 117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on Worth Venture Partners's 13F filing for Q4 2023, filed 9 Feb 2024.